Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 33,151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Healthy Participants
Interventions: PF-07853578, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Diarrhea Predominant Irritable Bowel Syndrome
Interventions: Serum-Derived Bovine Immunoglobulin, Placebo; Dietary Supplement · Other
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 8 Years to 18 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Obstructive Sleep Apnea
Interventions: Placebo oral capsule, LTM1201AZ, LTM1201AT, LTM1201AG, LTM1201AD; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intestinal Microbiota and Barrier Function
Interventions: Bifidobacteria adolescentis BD1, Bifidobacteria animalis subsp. lactis BB-12, Bifidobacteria adolescentis BD1 and galactooligosaccharide, Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide, galactooligosaccharide, Placebo; Dietary Supplement
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: Remicade; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Interstitial Cystitis/Painful Bladder Syndrome, Myofascial Pelvic Pain
Interventions: Metoprolol Tartrate Oral Tablet, Placebo Oral Tablet, No intervention- observational sub-study; Drug · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Evanston, Illinois • Richmond, Virginia

Conditions: Alcohol Dependence
Interventions: Prazosin Tablet, Placebo Tablet; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Local Muscular Endurance and Fatigue, NIRS Skeletal Muscle Mitochondrial Capacity, Acute Taurine Supplementation
Interventions: Acute Taurine Supplementation, Acute Placebo Supplementation; Dietary Supplement
Lead sponsor: Louisiana State University and A&M College; Other
Eligibility: 18 Years to 40 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Herpes Zoster Keratitis
Interventions: gancyclovir gel, Hypromellose gel; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 95 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cocaine Use
Interventions: l-tetrahydropalmatine (l-THP), Placebo; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Catonsville, Maryland

Conditions: Healthy Subjects
Interventions: oral spermidine; Dietary Supplement
Lead sponsor: Chrysea Labs Lda; Industry
Eligibility: 50 Years to 70 Years · Male only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Addison, Illinois

Conditions: Cannabis Use Disorder
Interventions: Lorcaserin, Placebo oral capsule; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 16
States / cities: Jonesboro, Arkansas • Fresno, California • Greenbrae, California + 13 more

Conditions: Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics
Interventions: Ranolazine, Verapamil, Lopinavir / Ritonavir, Chloroquine, Placebo, Dofetilide and Diltiazem; Drug
Lead sponsor: Food and Drug Administration (FDA); Federal
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Liraglutide, Saline; Drug
Lead sponsor: Ildiko Lingvay; Other
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Major Depressive Disorder, Depression, Healthy
Interventions: SP-624, Placebo; Drug
Lead sponsor: Sirtsei Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Garden Grove, California • Lincoln, Nebraska

Conditions: Alpha1-Antitrypsin Deficiency
Interventions: Fazirsiran Injection, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 15 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Sickle Cell Disease, Hb-SS Disease With Vasoocclusive Pain, Hemoglobin SS Disease With Vasoocclusive Crisis, Other Sickle Cell Disease With Vaso-Occlusive Pain, Hemoglobin SS Disease With Crisis
Interventions: Abciximab, Placebo, Intravenous hydration, Ibuprofen, Parenteral narcotic, Incentive spirometry, Supplemental oxygen; Drug · Other
Lead sponsor: St. Louis University; Other
Eligibility: 5 Years to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Safety, Tolerability, Pharmacokinetics, Healthy Participants
Interventions: AZD7503, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Glendale, California

Conditions: Facioscapulohumeral Muscular Dystrophy (FSHD)
Interventions: Placebo, ATYR1940; Biological
Lead sponsor: aTyr Pharma, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Rochester, New York • Columbus, Ohio

Conditions: Lung Transplant Infection
Interventions: Inhaled beclomethasone, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hemoglobinuria, Paroxysmal
Interventions: Eculizumab; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

A Study to Learn About the Study Medicine PF-07853578 and How it Acts in the Bodies of Healthy Adults

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

Pharmacological Activation of HMN for OSA Aim 2

Use of a Novel Synbiotic to Change Human Gut Bacteria and Improve Health in Obese Adults

Sleep and Immunity in Rheumatoid Arthritis : Remicade Substudy

Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis

Interstitial Cystitis: Examination of the Central Autonomic Network

Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse

Near-Infrared Spectroscopy, Acute Taurine Supplementation, and Isolated Muscular Endurance and Fatigue Resistance in Young Healthy Adults

Comparison of Topical 0.15% Gancyclovir Gel Versus 0.3% Hypromellose Gel for the Treatment of Herpes Zoster Keratitis

L-tetrahydropalmatine (l-THP) Treatment for Cocaine Use Disorder

Metabolic Responses to Spermidine Supplementation.

Lorcaserin for Cannabis Use Disorder

A Pilot Study of BMS-512148 in Subjects With Type 2 Diabetes

CiPA Phase 1 ECG Biomarker Validation Study

Adding Liraglutide to High Dose Insulin: Breaking the Cycle

A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression

Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD7503 in Healthy Participants

Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy

Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients

Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria